Maurizia Rossana Brunetto
YOU?
Author Swipe
View article: Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real‐World Database
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real‐World Database Open
Background and Aims Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data ar…
View article: Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study Open
Introduction: The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiolo…
View article: The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm
The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm Open
Background and Aim Ongoing migratory flows are reconstituting the hepatitis D virus (HDV) reservoir in Italy. We aimed to characterise the current clinical and virologic features of HDV infection in both native Italians and migrants. Metho…
View article: Outcome of hepatic resection for HCC in ideal and non-ideal candidates
Outcome of hepatic resection for HCC in ideal and non-ideal candidates Open
Background: The Barcelona Clinic Liver Cancer staging system considers, among patients with HCC, “ideal candidates” (ICs) for hepatic resection (HR) those with a single lesion, normal bilirubin, and without clinically significant portal hy…
View article: Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study Open
The criteria used to assess HCC recurrence risk in the IMbrave050 trial find validation by real-world data in patients treated with resection, while they are inaccurate after ablation.
View article: Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world Open
After the conditional approval of OCA for the treatment of PBC, the main confirmatory study failed to demonstrate OCA's ability to reduce liver-related events, leading the EMA to revoke the drug's marketing authorization. The ensuing scien…
View article: Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study
Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study Open
Background: Steatotic liver disease (SLD) is a growing global health concern and may progress to more advanced liver diseases (i.e., fibrosis, cirrhosis, and hepatocellular carcinoma). Early identification of individuals at risk through ef…
View article: The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals
The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals Open
The availability of highly effective direct-acting antivirals (DAAs) that cure individuals infected with HCV has changed completely the natural history of HCV infection and chronic hepatitis C. In sustained responders to DAAs, the most com…
View article: Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies Open
Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization established targets to el…
View article: P-2191. Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study
P-2191. Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study Open
Background Bulevirtide (BLV) is a first-in-class entry inhibitor for chronic hepatitis D (CHD) approved in Europe. Interim results from MYR301 (NCT03852719), a phase 3 randomized study, showed monotherapy with BLV 2 mg/d or 10 mg/d given s…
View article: Absence of Viral Replication Is Associated With Improved Outcome in Anti‐<scp>HCV</scp>‐Positive Patients With Hepatocellular Carcinoma
Absence of Viral Replication Is Associated With Improved Outcome in Anti‐<span>HCV</span>‐Positive Patients With Hepatocellular Carcinoma Open
Background and Aims Presence of active hepatitis C virus (HCV) infection may influence the outcome of patients treated for hepatocellular carcinoma (HCC), although this issue has never been adequately assessed in a large series of patients…
View article: Systemic Inflammatory Response Markers Improve the Discrimination for Prognostic Model in Hepatocellular Carcinoma
Systemic Inflammatory Response Markers Improve the Discrimination for Prognostic Model in Hepatocellular Carcinoma Open
Background/purpose of the study: We aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and their combination (combined NLR-PLR, CNP) on overall survival (OS) and recurrence-free su…
View article: Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48 Open
Background and Aims The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients with chronic hepatitis delta (CHD). Me…
View article: Cytoskeleton Remodeling-Related Proteins Represent a Specific Salivary Signature in PSC Patients
Cytoskeleton Remodeling-Related Proteins Represent a Specific Salivary Signature in PSC Patients Open
Primary sclerosing cholangitis (PSC) and Primary biliary cholangitis (PBC) are chronic inflammatory biliary diseases characterized by progressive damage of the bile ducts, resulting in hepatobiliary fibrosis and cirrhosis. Currently, speci…
View article: Development and Validation of a <scp>PIVKA</scp>‐<scp>II</scp>‐Based Model for <scp>HCC</scp> Risk Stratification in Patients With <scp>HCV</scp>‐Related Cirrhosis Successfully Treated With <scp>DAA</scp>
Development and Validation of a <span>PIVKA</span>‐<span>II</span>‐Based Model for <span>HCC</span> Risk Stratification in Patients With <span>HCV</span>‐Related Cirrhosis Successfully Treated With <span>DAA</span> Open
Background and Aims Patients with hepatitis C virus (HCV)‐related cirrhosis with sustained virological response (SVR) to direct‐acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein in…
View article: Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials Open
Summary Background In two phase 3 studies, tenofovir alafenamide (TAF) showed non‐inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB). Aims Her…
View article: An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference
An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference Open
Background & Aims There is an unmet need for a reliable and reproducible non‐invasive measure of fatty liver content (FLC) for monitoring steatotic liver disease in clinical practice. Sonographic FLC assessment is qualitative and operator‐…
View article: Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report
Stauffer syndrome in a tumor of the pancreatic tail: A paracrine pathogenesis, rather than an inflammatory disimmune phenomenon – a case report Open
Stauffer syndrome, also known as paraneoplastic intrahepatic cholestasis syndrome, is a rare reversible clinical manifestation characterized by elevation of direct bilirubin, alcaline phosphatase, transaminases and prolonged prothrombin ti…
View article: Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the <scp>DAA</scp> era and the <scp>COVID</scp>‐19 pandemic
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the <span>DAA</span> era and the <span>COVID</span>‐19 pandemic Open
HCV infection poses a global health threat, with significant morbidity and mortality. This study examines HCV trends in a large Italian region from 2015 to 2022, considering demographic changes, evolving clinical profiles, treatment regime…
View article: HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B Open
Objective Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of…